Medivir announces new studies in phase III program for TMC435

· Study in previous non-responder Hepatitis C genotype-1 infected patients · Study in Hepatitis C genotype-4 infected patients Huddinge, Sweden – MedivirAB (OMX: MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively. HPC3001HPC3001 is a phase III efficacy, safety and